Exclusive Summary

• - Full titration strengths available (3/7/14 mg) for the standard initiation-escalation regimen, offering a convenient oral GLP-1 option globally.
• - In major markets (US/EU/Japan), core and formulation patents run roughly to 2031–2033, with minimal generic presence, enabling first-mover entry where IP is not in force.
• - Massive unmet need: ~537 million adults with T2D globally, rising to ~783 million by 2045, with strong demand for effective oral therapies among injection-averse patients.
• - PIONEER data show HbA1c reductions ~1.0–1.4% and weight loss 3–5 kg; ADA/EASD recommend GLP-1RAs in multiple high-risk phenotypes.
• - CTD dossier ready (Pakistan) plus TT model supports rapid local registration and manufacturing, with typical 30–60% cost savings versus originator when legally permissible.

Asset Materials

Contact Us for Full Materials